Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helping HAND 4: Post-Discharge Tobacco Cessation Strategies
NCT03603496Phase 4
Key facts
- Status
- Completed
- Start
- Sep 2018
- Primary completion
- Nov 2020
- Countries
- 1
- Sponsor
- Massachusetts General Hospital
- Modality
- Transdermal Patches, Small Molecules
- Drugs
- nicotine patch
- Conditions
- Tobacco Use Disorder (TUD)
01
Overview
Phase 4, randomised, open-label trial of nicotine patch in Tobacco Use Disorder (TUD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Tobacco Abstinence, Biochemically Confirmed at 6 months. Started Sep 2018; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Transitional Tobacco Care Management
eReferral to State Tobacco Quitline
03
Who it enrols
Adult smokers admitted to a study hospital who plan to quit after discharge and were seen by a hospital smoking counselor.
04
Endpoints
Primary
Tobacco Abstinence, Biochemically Confirmed
Secondary
Tobacco Abstinence, Self-report
Engagement in Cessation Treatment
Self-reported Continuous Tobacco Abstinence Since Hospital Discharge
Beyond the preview
Go deeper on NCT03603496.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603496.